Julian Baker has served as a director of Genomic Health since January 2001. Mr. Baker is a managing partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family, now known as Baker/Tisch investments. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He is also a director of Incyte Corporation, Neurogen Corporation, Theravance, Inc. and Trimeris, Inc. Mr. Baker holds a Bachelor of Arts in Social Studies from Harvard University.

Felix Baker, Ph.D., Managing Partner, Baker Brothers Investments

Felix J. Baker, Ph.D., has served as a director of Genomic Health since 2012. Felix J. Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Company director Julian C. Baker, founded in 2000. Dr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a Bachelor of Science and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. Dr. Baker currently serves as a director of Seattle Genetics, Inc. and Synageva BioPharma Corp., both of which are publicly-traded biotechnology companies.

Fred Cohen, M.D., D. Phil., Partner, TPG

Fred E. Cohen, M. D., D. Phil., has served as a director of Genomic Health since April 2002. Dr. Cohen is a partner at TPG, a private equity firm which he joined in 2001. Dr. Cohen was a Professor of Medicine and Pharmacology at the University of California, San Francisco, where he taught from 1998 to 2014. Dr. Cohen serves as a director of BioCryst Pharmaceuticals, Inc., CareDx, Inc., FivePrime Therapeutics, Inc., Quintiles Transnational Holdings, Inc., Roka Bioscience, Inc., Tandem Diabetes Care, Inc., Veracyte, Inc. and other privately held companies. Dr. Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D. Phil. in Molecular Biophysics from Oxford University and an M. D. degree from Stanford University.

Henry J. Fuchs, M.D, has served as a director of Genomic Health since September 2013. Dr. Fuchs is the Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc., a biopharmaceutical company. From September 2005 to December 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company. From October 1996 until June 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences, Inc., a biotechnology company, first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as President and Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech Inc., a biotechnology company. Dr. Fuchs serves as a director of Mirati Therapeutics, Inc. and served as a director of Ardea Biosciences, Inc. from November 2001 to June 2012. Dr. Fuchs received a Bachelor of Arts degree in Biochemical Sciences from Harvard University, and an M.D. degree from George Washington University.

Ginger L. Graham, President and CEO, Two Trees Consulting and former President and CEO, Amylin Pharmaceuticals

Ginger L. Graham has served as a director of Genomic Health since 2008. Ms. Graham is a member of the Harvard Business School Health Industry Alumni Advisory Board, The University of Arkansas Chancellor’s Campaign Steering Committee, and the Advisory Board for the BioFrontiers Institute at the University of Colorado. She is also a director of Walgreen Co., the Proteus Digital Health Pharmaceutical Division, Surefire Medical, Elcelyx Therapeutics, and the Circle of Life Hospice Foundation. Ms. Graham serves on the Advisory Board for the Kellogg Center for Executive Women and co-chairs the Scientific Council of the University of Colorado’s Center for Women’s Health Research.

Randall Livingston, Vice President for Business Affairs and Chief Financial Officer, Stanford University

Randall Livingston has served as a director of Genomic Health since October 2004. In 2001, Mr. Livingston was appointed Vice President for Business Affairs and Chief Financial Officer of Stanford University. From 1999 to 2001, Mr. Livingston served as Executive Vice President and Chief Financial Officer of OpenTV Corp., a provider of interactive television services. From 1996 until 1999, Mr. Livingston served as a consultant and part-time executive for several Silicon Valley technology companies. Prior to 1996, Mr. Livingston worked for Heartport, Inc., Taligent, Apple Computer, Ingres Corporation and McKinsey & Company. Mr. Livingston holds a Bachelor of Science degree in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Geoffrey M. Parker, Member of the Board of Directors at ChemoCentryx, Inc. and Sunesis Pharmaceuticals, Inc.

Geoffrey M. Parker has served as a director of Genomic Health since June 2016. He is currently a member of the board of directors at ChemoCentryx, Inc and Sunesis Pharmaceuticals, Inc. Mr. Parker was the Executive Vice President of Anacor Pharmaceuticals, Inc. from May 2014 to May 2015. Additionally, he was the Chief Financial Officer of Anacor Pharmaceuticals, Inc. from September 2010 to May 2015. Mr. Parker served as the Vice President, Managing Director and Partner at the global investment banking and securities firm Goldman, Sachs & Co., leading their West Coast Healthcare Investment Banking practice from April 1997 to April 2009. During 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from the Stanford Graduate School of Business.

Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by Women Health Care Executives. Kim holds a Bachelor of Arts degree in Business from Michigan State University.